333 related articles for article (PubMed ID: 24351163)
21. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Hemoglobin; 2011; 35(3):186-98. PubMed ID: 21599431
[TBL] [Abstract][Full Text] [Related]
22. Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
Ha SY; Mok AS; Chu WC; Rasalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2011; 35(3):199-205. PubMed ID: 21599432
[TBL] [Abstract][Full Text] [Related]
23. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
[TBL] [Abstract][Full Text] [Related]
24. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
Huang YC; Chang JS; Wu KH; Peng CT
Hemoglobin; 2006; 30(2):229-38. PubMed ID: 16798648
[TBL] [Abstract][Full Text] [Related]
25. Iron-chelation therapy with oral chelators in patients with thalassemia major.
Uygun V; Kurtoglu E
Hematology; 2013 Jan; 18(1):50-5. PubMed ID: 23321010
[TBL] [Abstract][Full Text] [Related]
26. Evolution of OGTT in patients with beta-thalassaemia major in relation to chelation therapy.
Christoforidis A; Perifanis V; Tsatra I; Vlachaki E; Athanassiou-Metaxa M
Diabetes Res Clin Pract; 2007 Apr; 76(1):6-11. PubMed ID: 16930760
[TBL] [Abstract][Full Text] [Related]
27. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2010 Jun; 34(3):204-9. PubMed ID: 20524810
[TBL] [Abstract][Full Text] [Related]
28. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
Telfer PT; Warburton F; Christou S; Hadjigavriel M; Sitarou M; Kolnagou A; Angastiniotis M
Haematologica; 2009 Dec; 94(12):1777-8. PubMed ID: 19815834
[No Abstract] [Full Text] [Related]
29. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
Kuo HT; Tsai MY; Peng CT; Wu KH
Hemoglobin; 2006; 30(2):291-9. PubMed ID: 16798654
[TBL] [Abstract][Full Text] [Related]
30. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
Farmaki K; Angelopoulos N; Anagnostopoulos G; Gotsis E; Rombopoulos G; Tolis G
Br J Haematol; 2006 Aug; 134(4):438-44. PubMed ID: 16822284
[TBL] [Abstract][Full Text] [Related]
31. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
32. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
[No Abstract] [Full Text] [Related]
33. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
[TBL] [Abstract][Full Text] [Related]
34. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
35. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
36. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
[TBL] [Abstract][Full Text] [Related]
37. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
38. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
[TBL] [Abstract][Full Text] [Related]
39. Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study.
Drakonaki EE; Maris TG; Maragaki S; Klironomos V; Papadakis A; Karantanas AH
Hemoglobin; 2010; 34(1):95-106. PubMed ID: 20113293
[TBL] [Abstract][Full Text] [Related]
40. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
Porcu M; Landis N; Salis S; Corda M; Orrù P; Serra E; Usai B; Matta G; Galanello R
Eur J Heart Fail; 2007 Mar; 9(3):320-2. PubMed ID: 17029959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
